Radiation Therapy for Dupuytren's Disease

(Dupuytren's Trial)

BM
Overseen ByBruce McGibbon, MD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Yale University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a randomized study to determine whether radiation therapy reduces the risk of progression / recurrence of Dupuytren's disease / contracture.

Who Is on the Research Team?

BM

Bruce McGibbon, MD

Principal Investigator

Yale University

FD

Frank D Buono, PhD

Principal Investigator

Yale University

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with Dupuytren's disease or contracture who want to see if radiation can help prevent their condition from getting worse. Specific inclusion and exclusion criteria are not listed, so eligibility may depend on a doctor's assessment.

Inclusion Criteria

Patient consent
English-speaking
I do not have any diseases that make me sensitive to radiation.
See 5 more

Exclusion Criteria

Pregnancy or lactation
I have a genetic condition that makes me very sensitive to radiation.

What Are the Treatments Tested in This Trial?

Interventions

  • Radiation Therapy

Trial Overview

The study randomly assigns participants to receive either radiation therapy or standard care to find out if radiation helps stop Dupuytren's disease from progressing or coming back.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Radiation TherapyExperimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+